Recruiting
Secondary progressive multiple sclerosis
RecruitingA study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
- Sponsor:Novartis Pharma AG



